FDA granted 510(k) clearance for Tempus AI's ECG-Low EF software.
4 reports, 3 independent
Updated Jul 23
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted 510(k) clearance for Tempus AI's ECG-Low EF software.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- FDA granted 510(k) clearance for combined technologies for Solventum.
- The FDA granted 510(k) clearance to SimBioSys's software.
- Providence Medical Technology, Inc. received 510(k) clearance from the FDA and plans to showcase its system at the Henry B. González Convention Center.
- Tempus listed on the NASDAQ stock exchange, providing diagnostic data and AI tools to facilitate drug approval processes.
Coverage
Newest first; wire copies grouped- ZacksTempus AI Gains FDA Nod Amid Booming AI ECG Market Momentum The integration of artificial intelligence (AI) in the cardiovascular space, particularly in electrocardiography (ECG), is reshaping clinic
- Simply Wall St.Tempus AI (TEM) Gains FDA Clearance for New Cardiovascular Risk Detection Software Tempus AI has recently secured FDA clearance for its Tempus ECG-Low EF software, an innovative AI-driven product aid
- ZacksTEM Shares Surge on New AI Breakthrough: Should Investors Jump In? Tempus AI TEM jumped 7.3% at yesterday’s close after securing FDA 510(k) clearance for its ECG-Low EF software, its second greenligh
- Business WireTempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-Low EF Software CHICAGO, July 16, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to adv